Hedge funds have been steadily buying Pfizer shares, attracted by its 6.3% dividend yield and promising oncology drug pipeline. Despite challenges from upcoming patent expirations that could impact earnings, Pfizer's late-stage cancer treatments and AI-driven biotech advancements offer potential for growth. The company’s recent stock rally and strategic acquisitions like Seagen suggest it might better navigate the patent cliff than expected. Investors see Pfizer as a value opportunity with a strong dividend and growth prospects amid a volatile market environment.
Pfizer, Chevron, and AbbVie have delivered strong dividend returns in 2026 and are positioned for further growth in 2027. Pfizer aims for $35 per share driven by obesity and oncology products, Chevron targets $250 supported by Guyana projects and AI ...
In 2026, Merck's stock surged 44% year-to-date, outperforming major U.S. drugmakers Amgen (up 35%) and Pfizer (up 14%). Merck's success is driven by its strong oncology portfolio, including the top-selling cancer drug KEYTRUDA, and diverse products b...
Fairholme Capital, led by Bruce Berkowitz, holds 76.43% of its portfolio in St. Joe Company, a Northwest Florida land developer, reflecting strong conviction as the company posted its highest Q2 revenue in 20 years with significant margin expansions....
Kailera Therapeutics recently closed at $18.51, down 2.5% for the week and 28.8% since its April IPO. The clinical-stage company, with no product revenue, holds $1.17 billion in cash and has a runway into mid-2028. Its lead drug, ribupatide, is in gl...
Pfizer is considered a cautious Buy, trading near its intrinsic value with an expected 10% annual return mainly from its high dividend yield. However, the company faces significant challenges including a looming patent cliff, a stretched balance shee...
